IL22 and psoriasis: In imiquimod (IMQ)-induced psoriasis mouse models, psoriasis-like pathological changes in systemic as well as KCs-specific IL36R −/− mice were significantly improved compared with wild-type mice, and mRNA levels of cytokines such as IL-17A, IL-17C, IL-22, and IL-23 in lesional skin lesions were also significantly reduced (17).